Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891168 | 0.90 | GRIA1 (0.52) | GRIA1GRIA3PDE4DACVR1BTGFBR1 | |
| SCHEMBL1882345 | 0.86 | GRIA1 (0.50) | GRIA1GRIA3PDE4DACVR1BTGFBR1 | |
| SCHEMBL1883836 | 0.85 | GRIA1 (0.59) | GRIA1GRIA3PDE4DTGFBR1SRC | |
| SCHEMBL1884749 | 0.83 | GRIA1 (0.53) | GRIA1GRIA3PDE4DMCHR1SRC | |
| SCHEMBL1884211 | 0.83 | GRIA1 (0.48) | GRIA1GRIA3PDE4DACVR1BTGFBR1 | |
| SCHEMBL1883904 | 0.83 | GRIA1 (0.59) | GRIA1GRIA3PDE4DSRCLYN | |
| SCHEMBL7021080 | 0.82 | GRIA1 (0.46) | GRIA1GRIA3PDE4DACVR1BTGFBR1 | |
| SCHEMBL1890140 | 0.82 | GRIA1 (0.67) | GRIA1GRIA3PDE4DTGFBR1SRC | |
| SCHEMBL1884948 | 0.82 | GRIA1 (0.70) | GRIA1GRIA3PDE4DTGFBR1SRC | |
| SCHEMBL1881496 | 0.82 | GRIA1 (0.49) | GRIA1GRIA3PDE4DACVR1BTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7759367-B2 | 1,2-dihydropiridin-2-one compounds such as 3-(2-cyanophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one, used as immunomodulators or antiinflammatory agents, and for the prevention or treatment of neurodegenerative diseases, such as demyelinating disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-2177520-A1 | 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | NAGATO SATOSHI | 2009-11-05 | — | — | US | disclosed |
| US-7563811-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| EP-2053041-A2 | 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease | Eisai R&D Management Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
| EP-1300396-B1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-01-14 | — | — | EP | disclosed |
| EP-1465626-B1 | PHARMACEUTICAL COMPOSITIONS (KIT) COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY (OR AN ANTIINFLAMMATORY) AGENT AND THEIR USES | EISAI R&D MAN CO LTD (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | GRIK1, GRIK2, GRIK4 | GRIA1 14/4885GRIA3 58/4885PDE4D 2584/4885 |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | GRIK1, GRIK2, GRIK5 | GRIA1 24/4885GRIA3 46/4885PDE4D 1607/4885 |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | QDPR, PMP22, MAG | GRIA1 449/4885GRIA3 663/4885PDE4D 679/4885 |
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | GRIK1, GRIK2, GRIK5 | GRIA1 20/4885GRIA3 28/4885PDE4D 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.